Developing treatments for the diseases that are hardest to treat
We wholly own a platform with the potential for treating cancer and selecting patients who would likely benefit from the treatment. Endocyte technology is in mid-stage clinical trials.
|PROGRAM||INDICATION||PHASE||PRECLINICAL||PHASE 1||PHASE 2||PHASE 3||PARTNERS|
|Radioligand Therapy (RLT)|
|177Lu-PSMA-617||mCRPC||PHASE 2 (Phase 3 1H 2018)||1H 2018|
|177Ac-PSMA-617||mCRPC||PHASE 1 (Phase 2 4Q 2017)||4Q 2017|
|225Ac-PSMA-617||mCRPC||PRECLINICAL (Phase 1 1H 2018)||1H 2018|
|CAR T (Adapter Controlled)|
|Fluorescein CAR T-Cell (FITC CAR T)|
|FITC CAR T + FITC-Folate CAM||Osteosarcoma||PRECLINICAL (Phase 1 2H 2018)||2H 2018|
|FITC CAR T + FITC-CAMs against various targets||Solid Tumors||PRECLINICAL|
* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.